Navigation Links
New Executive Vice President Commercial Appointed
Date:5/15/2012

STOCKHOLM, May 15, 2012 /PRNewswire/ --

Medivir AB (OMX: MVIR), a research-based specialty pharmaceutical company focused on infectious diseases, announced today that it has appointed Henric Juserius to be the new head of the company's commercial activities. Henric, who will have overall responsibility for Medivir's pharmaceutical marketing and sales, will join the company in August 2012 and will be part of the management team.

Henric Juserius has a degree in business administration and most recently held the position as Commercial Director for the Nordic region at Actelion Pharmaceuticals. He has an extensive experience from the industry and has worked with pharmaceutical marketing and sales for more than 20 years in companies such as Astra, GlaxoWellcome, Pfizer, Serono and Actelion.

"I am very pleased to welcome Henric Juserius to Medivir as Executive Vice President, Commercial. His extensive experience and broad expertise in marketing and sales of prescription drugs from both large and small pharmaceutical companies will be invaluable now that Medivir is approaching a market launch in the Nordic countries of its flagship product for hepatitis C, TMC435. Henric will also work on the development of Medivir's existing portfolio of prescription drugs," says Maris Hartmanis, President and CEO of Medivir.


About Medivir

Medivir is an emerging research-based specialty pharmaceutical company focused on the development of high-value treatments for infectious diseases. Medivir has world class expertise in polymerase and protease drug targets and drug development which has resulted in a strong infectious disease R&D portfolio. The Company's key pipeline asset is TMC435, a novel protease inhibitor in phase III clinical development for hepatitis C that is being developed in collaboration with Janssen Pharmaceuticals.

In June 2011, Medivir acquired the specialty pharmaceutical company BioPhausia to ensure timely commercialisation of TMC435 in the Nordic markets, once approved.

Medivir's first product, the unique cold sore product Xerese®/Xerclear®, was launched on the US market in 2011. Xerese®/Xerclear®, which has been approved in both the US and Europe, is being launched in collaboration with GlaxoSmithKline to be sold OTC in Europe, Japan and Russia. Rights in North America, Canada and Mexico were sold to Meda AB in June 2011. Medivir has retained the Rx rights for Xerclear® in Sweden and Finland.

For more information on Medivir, please see the company's website:  http://www.medivir.com

 

For more information, please contact

Rein Piir, EVP Corporate Affairs & IR, Office line +46-8-440-6550 or Mobile +46-708-537292, Maris Hartmanis, CEO, +46-8-407-64-30


'/>"/>
SOURCE Medivir AB
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Global HIV Vaccine Enterprise Names Alan Bernstein as Inaugural Executive Director, Opens New Secretariat
2. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation
3. Industry Executives Finding Value in Shift of Scientific Publications
4. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Bioniche Life Sciences Inc.
5. Evalve Expands Executive Leadership Team
6. ParagonRx Names Ellen M. Derrico To Chief Marketing Executive Post
7. Tata Interactive Systems Partners With Bersin & Associates for Exclusive Executive Learning Forum - TLF 2009
8. Premier Research Appoints Troy W. McCall, Ph.D. as Chief Executive Officer
9. Delcath Systems, Inc. Appoints Dr. Krishna Kandarpa its Executive Vice President R&D and Chief Medical Officer
10. Lincare Holdings Inc. Extends Terms of Employment Agreements with Executive Officers
11. Curemark Announces Senior Executive Promotions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/5/2017)... 2017 The Cincinnati location ... Inc. (NYSE: DPLO), has been awarded a Top Workplaces ... Results are based on an employee survey administered by ... workplace improvement. The survey measures several aspects of workplace culture, ... ...
(Date:5/30/2017)... , May 30, 2017 DarioHealth Corp. (NASDAQ: DRIO), a ... solutions, today announced that it will be presenting at the 7th ... AM PT. Erez Raphael , CEO, of DarioHealth will be ... will be held on June 6th & 7th, 2017 at the ... the small / micro-cap space. ...
(Date:5/26/2017)... SANTA BARBARA, Calif. , May 25, 2017 /PRNewswire-USNewswire/ ... the United States , Direct Relief is working ... of overdose-reversing Naloxone available at no cost to community ... and other nonprofit providers nationwide. "Pfizer ... expanding access to medicines and ensuring patient safety through ...
Breaking Medicine Technology:
(Date:6/28/2017)... ... 28, 2017 , ... The Wharton School’s Aresty Institute of ... a kick-off to the fifth annual CEO Connection Mid-Market Convention. , The ... Pennsylvania campus, followed by the two-day convention, which will target C-suite executives in ...
(Date:6/28/2017)... ... June 28, 2017 , ... Schneider ... planning assistance to clients in southern Montana, is announcing a focused charity effort ... , The outreach programs offered by Zoo Montana provide students with current knowledge ...
(Date:6/27/2017)... ... June 27, 2017 , ... Excel Medical, the leader ... the position of Executive Vice President, Sales and Marketing. Finnegan is a widely ... medical device sales leadership. He has received industry recognition for innovations and new ...
(Date:6/27/2017)... Orlando, FL (PRWEB) , ... June 27, 2017 ... ... the leading payment solution for many of the health care industry’s hospitals and ... its new patient financing portal for select customers. Parasail Health is a San ...
(Date:6/27/2017)... , ... June 27, 2017 , ... A January 18th ... projected to reach a staggering $6.81 billion by the year 2024 according to a ... a faster rate than those made from titanium. Los Angeles area clinic Beverly Hills ...
Breaking Medicine News(10 mins):